SI1701941T1 - Spojine za zdravljenje celičnih proliferativnih bolezni - Google Patents
Spojine za zdravljenje celičnih proliferativnih bolezniInfo
- Publication number
- SI1701941T1 SI1701941T1 SI200431908T SI200431908T SI1701941T1 SI 1701941 T1 SI1701941 T1 SI 1701941T1 SI 200431908 T SI200431908 T SI 200431908T SI 200431908 T SI200431908 T SI 200431908T SI 1701941 T1 SI1701941 T1 SI 1701941T1
- Authority
- SI
- Slovenia
- Prior art keywords
- compounds
- treatment
- cell proliferative
- proliferative diseases
- diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52887703P | 2003-12-11 | 2003-12-11 | |
| EP04813958A EP1701941B1 (en) | 2003-12-11 | 2004-12-13 | Compounds for treatment of cell proliferative diseases |
| PCT/US2004/041712 WO2005058829A1 (en) | 2003-12-11 | 2004-12-13 | Compounds for treatment of cell proliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1701941T1 true SI1701941T1 (sl) | 2012-09-28 |
Family
ID=34699909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200431908T SI1701941T1 (sl) | 2003-12-11 | 2004-12-13 | Spojine za zdravljenje celičnih proliferativnih bolezni |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US7745468B2 (https=) |
| EP (2) | EP2487156B1 (https=) |
| JP (1) | JP4751336B2 (https=) |
| KR (2) | KR101218633B1 (https=) |
| CN (2) | CN102603565A (https=) |
| AU (1) | AU2004298511B2 (https=) |
| BR (1) | BRPI0416981A (https=) |
| CA (1) | CA2548152C (https=) |
| DK (1) | DK1701941T3 (https=) |
| ES (1) | ES2385831T3 (https=) |
| IL (1) | IL176028A (https=) |
| MX (1) | MXPA06006460A (https=) |
| PL (1) | PL1701941T3 (https=) |
| PT (1) | PT1701941E (https=) |
| SI (1) | SI1701941T1 (https=) |
| WO (1) | WO2005058829A1 (https=) |
| ZA (1) | ZA200604682B (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1701941E (pt) | 2003-12-11 | 2012-08-03 | Univ Texas | Compostos para o tratamento de doenças proliferativas celulares |
| NZ567266A (en) | 2005-10-13 | 2010-09-30 | Orchid Res Lab Ltd | Carbazole derivatives as pSTAT3/IL-6 inhibitors (carvedilol) |
| BRPI0709916B8 (pt) | 2006-03-31 | 2021-05-25 | Univ Texas | drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas |
| WO2008005954A2 (en) * | 2006-06-30 | 2008-01-10 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
| AU2007322033B2 (en) | 2006-11-20 | 2013-07-11 | President And Fellows Of Harvard College | Methods, compositions, and kits for treating pain and pruritis |
| US20080167277A1 (en) * | 2006-12-29 | 2008-07-10 | Charles Conrad | Methods of treating skin disorders with caffeic acid analogs |
| US20100144802A1 (en) * | 2007-03-28 | 2010-06-10 | Heimberger Amy B | Small Molecule Inhibitors for Immune Modulation |
| EP3050566B1 (en) | 2007-09-10 | 2018-11-28 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| NZ590372A (en) | 2008-07-08 | 2012-09-28 | Univ Texas | Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats) |
| WO2010039609A2 (en) | 2008-09-30 | 2010-04-08 | Mallinckrodt Inc. | A version of fdg detectable by single-photon emission computed tomography |
| US8450337B2 (en) | 2008-09-30 | 2013-05-28 | Moleculin, Llc | Methods of treating skin disorders with caffeic acid analogs |
| WO2010081158A2 (en) * | 2009-01-12 | 2010-07-15 | The Board Of Regents Of The University Of Texas System | Blood test for the detection of cancer |
| JP6205133B2 (ja) | 2009-07-10 | 2017-09-27 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー |
| MX2012004363A (es) | 2009-10-16 | 2012-05-22 | Bayer Cropscience Ag | Aminopropenoatos como fungicidas. |
| US20130129675A1 (en) | 2009-12-04 | 2013-05-23 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
| WO2011097522A2 (en) * | 2010-02-05 | 2011-08-11 | Whitehead Institute For Biomedical Research | Combination methods for treatment of disease |
| EP2547205B1 (en) | 2010-03-19 | 2024-03-20 | 1Globe Biomedical Co., Ltd. | Novel methods for targeting cancer stem cells |
| EP2619184B1 (en) | 2010-09-24 | 2018-05-23 | The Regents of the University of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| EP2510787A1 (en) | 2011-04-15 | 2012-10-17 | Bayer Cropscience AG | Propenoates as fungicides |
| JPWO2012165262A1 (ja) | 2011-05-27 | 2015-02-23 | 国立大学法人徳島大学 | ベンジルアミン誘導体 |
| WO2013009872A1 (en) | 2011-07-11 | 2013-01-17 | The Regents Of The University Of Michigan | Multimodality left atrial appendage occlusion device |
| CA2874057A1 (en) * | 2012-05-25 | 2013-11-28 | The Governing Council Of The University Of Toronto | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
| CA2884309A1 (en) | 2012-09-07 | 2014-03-13 | Massachusetts Eye And Ear Infirmary | Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity |
| US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| EP2983790A2 (en) | 2013-04-09 | 2016-02-17 | Boston Biomedical, Inc. | Methods for treating cancer |
| WO2015002766A1 (en) | 2013-07-02 | 2015-01-08 | Nikolai Khodarev | Anti-tumor therapy |
| US9868736B2 (en) | 2013-10-10 | 2018-01-16 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| EP3212773B1 (en) | 2014-10-29 | 2021-09-15 | Massachusetts Eye and Ear Infirmary | Efficient delivery of therapeutic molecules to cells of the inner ear |
| AU2016301282B2 (en) | 2015-08-03 | 2022-03-17 | Children's Medical Center Corporation | Charged ion channel blockers and methods for use |
| JP7106563B2 (ja) | 2016-11-29 | 2022-07-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | ナフトフラン誘導体、その調製、および使用方法 |
| CA3062656A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
| TWI846678B (zh) | 2017-11-10 | 2024-07-01 | 美國德州系統大學評議委員會 | 咖啡酸衍生物及其用途 |
| WO2019148067A1 (en) | 2018-01-26 | 2019-08-01 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss |
| US10786485B1 (en) | 2019-03-11 | 2020-09-29 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| BR112021017809A2 (pt) | 2019-03-11 | 2021-11-23 | Nocion Therapeutics Inc | Bloqueadores de canais iônicos substituídos por éster e métodos para uso |
| AU2020234961C1 (en) | 2019-03-11 | 2025-08-14 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CN113811305A (zh) | 2019-03-11 | 2021-12-17 | 诺西恩医疗公司 | 带电的离子通道阻滞剂及其使用方法 |
| CN113891709A (zh) * | 2019-04-02 | 2022-01-04 | 德克萨斯大学系统董事会 | 用于治疗疾病的转录抑制剂和免疫检验点抑制剂的组合 |
| TWI875749B (zh) | 2019-04-05 | 2025-03-11 | 美商凱麥拉醫療公司 | Stat降解劑及其用途 |
| WO2021091585A1 (en) | 2019-11-06 | 2021-05-14 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| WO2021091586A1 (en) | 2019-11-06 | 2021-05-14 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US11332446B2 (en) | 2020-03-11 | 2022-05-17 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CN115381822A (zh) * | 2022-05-11 | 2022-11-25 | 暨南大学附属第一医院（广州华侨医院） | 一种基于激活免疫应答治疗肺癌的药物及制药应用 |
| KR102811597B1 (ko) * | 2022-06-22 | 2025-05-22 | 한국생명공학연구원 | 신규한 신남아마이드 유도체 및 이의 용도 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2555789A1 (de) * | 1975-12-11 | 1977-07-07 | Hoechst Ag | Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel |
| FR2629455B1 (fr) | 1988-03-29 | 1991-09-27 | Rhone Poulenc Agrochimie | Derives de 2-(3-pyridinyl)3-(phenoxy) propanenitrile |
| GB9004483D0 (en) * | 1990-02-28 | 1990-04-25 | Erba Carlo Spa | New aryl-and heteroarylethenylene derivatives and process for their preparation |
| CA2080582A1 (en) | 1990-04-16 | 1991-10-17 | Alfred P. Spada | Heterocyclicethenediyl compounds which inhibit egf receptor tyrosine kinase |
| US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
| CA2080554A1 (en) * | 1991-10-15 | 1993-04-16 | Mitsubishi Chemical Corporation | Styrene derivatives |
| JPH05301838A (ja) * | 1991-10-15 | 1993-11-16 | Mitsubishi Kasei Corp | スチレン誘導体 |
| CA2092017A1 (en) | 1992-03-26 | 1993-09-27 | Tameo Iwasaki | Butadiene derivatives and process for preparing the same |
| US5981569A (en) | 1992-11-13 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease |
| JPH06247850A (ja) | 1993-02-24 | 1994-09-06 | Suntory Ltd | １２−リポキシゲナーゼ阻害剤 |
| DE69414394T2 (de) | 1993-07-27 | 1999-05-12 | The University Of Birmingham, Edgbaston, Birmingham | Strassendecken |
| GB9322781D0 (en) * | 1993-11-04 | 1993-12-22 | Roussel Lab Ltd | Aromatic amides |
| IL107736A (en) | 1993-11-24 | 2001-01-11 | Yissum Res Dev Co | Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases |
| IL112205A0 (en) | 1994-01-06 | 1995-03-15 | Res Dev Foundation | Curcumin, analogues of curcumin and novel uses thereof |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| GB9406137D0 (en) * | 1994-03-28 | 1994-05-18 | Erba Carlo Spa | N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation |
| EP0754038A1 (en) | 1994-04-22 | 1997-01-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of benzylidene-malononitrile derivates for the treatment of leukemia |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| IL119069A0 (en) | 1996-08-14 | 1996-11-14 | Mor Research Applic Ltd | Pharmaceutical composition comprising tyrphostins |
| US5854285A (en) | 1997-04-03 | 1998-12-29 | Natpro, Inc. | Protein kinase inhibitor |
| US6420338B1 (en) | 1997-06-13 | 2002-07-16 | New York University Medical Center | Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
| CA2298480A1 (en) | 1997-07-25 | 1999-02-04 | Tsumura & Co. | Pyridylacrylamide derivatives and nephritis remedies and tgf-.beta. inhibitors containing the same |
| US6225346B1 (en) | 1997-10-24 | 2001-05-01 | Sugen, Inc. | Tyrphostin like compounds |
| EP1086957A4 (en) | 1999-03-04 | 2005-08-31 | Riken | CATALYST COMPOSITION |
| US20020045191A1 (en) | 2000-09-15 | 2002-04-18 | Schneider Robert J. | Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
| JP2003119169A (ja) | 2001-07-30 | 2003-04-23 | Shigetoshi Kadota | 細胞毒性活性を有する化合物およびそれを有効成分とする医薬組成物 |
| US6433018B1 (en) | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
| WO2003045367A1 (en) | 2001-11-30 | 2003-06-05 | Santen Pharmaceutical Co., Ltd. | Angiogenesis inhibitor |
| WO2003068157A2 (en) | 2002-02-11 | 2003-08-21 | The Brigham And Women's Hospital, Inc. | Kinase inhibitors and methods of use thereof |
| EP1581510A4 (en) | 2002-11-22 | 2006-08-30 | Bristol Myers Squibb Co | 1-ARYL-2-HYDROXYETHYLAMIDEALS CALIUM CHANNEL OPENER |
| KR20050055479A (ko) | 2003-12-08 | 2005-06-13 | 김철호 | 카페인산 또는 카페인산 페네틸에스테르를 유효성분으로하는 ｍｍｐ-9 억제제 |
| PT1701941E (pt) | 2003-12-11 | 2012-08-03 | Univ Texas | Compostos para o tratamento de doenças proliferativas celulares |
| BRPI0709916B8 (pt) * | 2006-03-31 | 2021-05-25 | Univ Texas | drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas |
| WO2008005954A2 (en) | 2006-06-30 | 2008-01-10 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
| US8741342B2 (en) * | 2006-10-30 | 2014-06-03 | Wockhardt Research Centre | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa |
-
2004
- 2004-12-13 PT PT04813958T patent/PT1701941E/pt unknown
- 2004-12-13 KR KR1020117027869A patent/KR101218633B1/ko not_active Expired - Fee Related
- 2004-12-13 CN CN2012100233394A patent/CN102603565A/zh active Pending
- 2004-12-13 EP EP12167605.0A patent/EP2487156B1/en not_active Expired - Lifetime
- 2004-12-13 PL PL04813958T patent/PL1701941T3/pl unknown
- 2004-12-13 AU AU2004298511A patent/AU2004298511B2/en not_active Ceased
- 2004-12-13 CN CN2004800370450A patent/CN1894215B/zh not_active Expired - Fee Related
- 2004-12-13 ES ES04813958T patent/ES2385831T3/es not_active Expired - Lifetime
- 2004-12-13 JP JP2006544085A patent/JP4751336B2/ja not_active Expired - Fee Related
- 2004-12-13 KR KR1020067013861A patent/KR101170655B1/ko not_active Expired - Fee Related
- 2004-12-13 BR BRPI0416981-6A patent/BRPI0416981A/pt not_active IP Right Cessation
- 2004-12-13 US US11/010,834 patent/US7745468B2/en active Active
- 2004-12-13 CA CA2548152A patent/CA2548152C/en not_active Expired - Lifetime
- 2004-12-13 DK DK04813958.8T patent/DK1701941T3/da active
- 2004-12-13 WO PCT/US2004/041712 patent/WO2005058829A1/en not_active Ceased
- 2004-12-13 MX MXPA06006460A patent/MXPA06006460A/es active IP Right Grant
- 2004-12-13 EP EP04813958A patent/EP1701941B1/en not_active Expired - Lifetime
- 2004-12-13 SI SI200431908T patent/SI1701941T1/sl unknown
-
2006
- 2006-05-30 IL IL176028A patent/IL176028A/en active IP Right Review Request
- 2006-06-07 ZA ZA2006/04682A patent/ZA200604682B/en unknown
-
2010
- 2010-06-28 US US12/824,901 patent/US8119827B2/en not_active Expired - Fee Related
-
2012
- 2012-01-13 US US13/350,637 patent/US8648102B2/en not_active Expired - Fee Related
-
2014
- 2014-01-03 US US14/147,089 patent/US9096499B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL176028A0 (en) | Compounds for treatment of cell proliferative diseases | |
| IL227841A0 (en) | Dihydropyridinones for the treatment of cancer | |
| ZA200508427B (en) | Methods for treating interleuking-6 related diseases | |
| IL172346A0 (en) | Treatment of t cell mediated diseases by inhibition of fgfr3 | |
| IL178860A (en) | Certain chemical entities, preparations and processes | |
| IL180729A0 (en) | Compounds and methods for treatment of cancer | |
| IL181305A0 (en) | Combinations for the treatment of diseases involving cell proliferation | |
| PL375532A1 (en) | Benzimidazol-1-yl-thiophene compounds for the treatment of cancer | |
| PL2001892T3 (pl) | Imidazolotiazolowe związki do leczenia chorób proliferacyjnych | |
| IL173386A0 (en) | Use of adcc-optimized antibodies for treating weak patients | |
| GB0329874D0 (en) | Compounds useful for the treatment of diseases | |
| SI1685125T1 (sl) | Derivati pirola, primerni za zdravljenje proliferativnih bolezni | |
| GB0305150D0 (en) | Use of therapeutic compounds | |
| IL175535A0 (en) | Compositions for treatment of neurodegenerative diseases | |
| EP1709155A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF DYSPROLIFERATIVE DISEASES AND METHODS OF THEIR USE | |
| PL1801108T3 (pl) | Związki morfolinowe do leczenia stanów zapalnych | |
| GB0400802D0 (en) | Compounds for the treatment of disease | |
| PL1742937T3 (pl) | Pochodne pirolopirymidynowe do leczenia chorób proliferacyjnych | |
| SI1535612T1 (sl) | Zdravljenje hiperurikemije | |
| ZA200606780B (en) | Compounds for the treatment of diseases | |
| IL175611A0 (en) | Combinations for the treatment of proliferative diseases | |
| AP2006003728A0 (en) | Compounds for treatment of diseases | |
| GB0425073D0 (en) | Compounds for the treatment of diseases | |
| GB0420867D0 (en) | Compounds for the treatment of diseases | |
| GB0425064D0 (en) | Compounds useful for the treatment of diseases |